Update from the American Association for the Study of Liver Diseases Meeting

The UC San Diego AntiViral Research Center sponsors weekly presentations by infectious disease clinicians, physicians and researchers. The goal of these presentations is to provide the most current research, clinical practices and trends in HIV, HBV, HCV, TB and other infectious diseases of global significance. The slides from the AIDS Clinical Rounds presentation that you are about to view are intended for the educational purposes of our audience. They may not be used for other purposes without the presenter’s express permission.

AIDS CLINICAL ROUNDS

UPDATE'FROM'AASLD'

Presented'by'Laurel'and'Hardy'

•  we'talk'about'our'pt'and'both'his'ini@al'treatment'op@ons'for'a'guy'on'TDF/FTC/RAL/DRV/rit'and'how'we'are'trying'to'accommodate'SOF/SMV'now'with'his'HIV'regimen…'

'•  Drug'interac@ons'with'ARVs''(Richard):'•  Mdrug'interac@on'data'•  MHIV'data'with'SOF/NS5a'regimen'(NIH'study'presented'at'AASLD'with'

SOF/LDV)'•  Mother'HIV'data'(AbbVie'data'Turquoise'I)'

•  Retreatment'of'SOF'and/or'other'HCV'failures/resistance'(David):'•  M'retereatment'data'(Gilead'1118'study;'data'from'real'world'cohorts)'•  M'resistance'issues'(NS5A'impact'focus)'•  Mfuture'regimens'that'might'address'resistance'if'needed.'

GJ'•  57'AA'yo'male'•  HCV'

– Genotype'1a'– Cirrhosis'F5/6'(bx'3/2014);'no'decompensa@on'– U/S'nega@ve'1/2014;'EGD'w/o'varicies''– Null'responder'to'PEG/'RBV'– Relapse'a`er'12'weeks'SOF/'DVC'

•  PMH'– DMII;'HTN'– HBV'and'HAA'immune'

HIV'Treatment'Hx'•  5/13M9/14:'DRVr'(BID)/'RAL/'TDF/'FTC'

–  1/09M5/13:'SQV(BID)/'RAL/'TDF/FTC'2004M'09:'TDF/CBV/SQV(1000)'BID/RTV(100)'BID'

–  2000M04:'D4T/3TC/IDV/RTV''–  Late'1990s'x'2'weeks:'ZDV'+'2'others?''

•  Phenotype'2004:''–  NRTI'M'Sensi@ve'to'ABC,'ddI,'d4T,'TDF,'ZDV.'Reduced'suscep@bility'to'FTC,'3TC''

–  NNRTI'M'Sensi@ve'to'EFV,'NVP,'DLV''–  PI'M'Sensi@ve'to'SQV.'Reduced'suscep@bility'to'ATV,'FPV,'IDV,'LPV,'NFV,'RTV'

What'HCV'regimen'can'be'given'with'his'current'ARV'regimen?'

•  SOF/'LDV'•  SIM/'SOF'•  SIM/'SOF'RBV'•  IFN/'RBV/'SOF'•  none'

Labs'10/2014'

•  Chemistry:''–  Cr.'1.3;'AST'39;'ALT'25;'TB'0.5'

•  CBC:'– Hg'14.3;'plt'107;'INR'1.0'

•  HCV'RNA:'3,457,502'•  APRI'='0.91'(cutoff'1.0);'Fib'4'='4.2'(cutoff'1.45)'•  CD4:'509'(33%)'•  HIV'RNA:'25'(<20'on'9/19/14)'

Significant'drug'interac@ons'of'ARV'and'SOF'include?'

1.  TDF'2.  All'PIs'3.  All'NNRTIs'4.  RAL'but'not'other'INSTI'5.  none'

Significant'drug'interac@ons'of'ARV'and'SIM'include?'

1.  All'NRTI'2.  Some'NNRTI'3.  All'PI'boosted'with'RTV'or'cobi'4.  2'and'3'5.  none'

Significant'drug'interac@ons'of'ARV'and'SOF/LDV'include?'

1.  All'NRTI'2.  TDF'when'given'with'EFV'or'ETR'3.  TDF'when'given'with'a'PIr'4.  All'PI'5.  2'M'4''

SIM'Metabolism'

•  SIM'metabolized'by'CYP'3A'– CYP3A'inhibitors'increase'SIM'– CYP3A'inducers'decrease'SIM'

•  SIM'inhibits'intes@nal'CYP3A'but'not'hepa@c'•  SIM'inhibits'OATP1B1/3'and'PGP'

DDI'between'NRTI'and'HCV'Agents'

ARV$ SOF$ LDS/$SOF$ SIM$

FTC/$3TC$ 00$ 00$ 00$

ABC$ 00$ 00$ 00$

TDF$ 00$ ✖ PIr$$! TDF$

00$

ZDV$ 00$ 00$ 00$

MM'='no'significant'effect'✖''='do'not'use'

AASLD/IDSA/IAS–USA.'hpp://www.hcvguidelines.org.'hpp://aidsinfo.nih.gov/contenqiles/lvguidelines/AdultandAdolescentGL.pdf'

DDI'between'TDF'and'LDV/'SOF'

•  C24'geometric'mean'ra@o:'2.6'(90%'CI:'2.4M'3.0)'•  no'effect'='1.0'•  TFV'levels'similar'to'dosing'with'DRVr'+'TDF'

Similar'data'with'RPV'as'EFV'

German'et'al.'15th'Clinical'Pharmacology'Workshop'of'HIV'&'HCV;'2014:'OM06'

DDI'between'TDF'and'LDV/'SOF'

•  Drug'interac@on'data'with'PIr'+'TDF'+'LDV/SOF'is'not'available'

•  DRVr'increases'LDV'(GMR'='1.39)'•  TFV'levels'are'expected'to'be'higher'with'PIr'and'LDV/SOF'

AASLD/IDSA/IAS–USA.'hpp://www.hcvguidelines.org.'

DDI'between'NNRTI'and'HCV'Agents'


EFV$ 00$ 00$(TDF$!)$

✖EFV00$SIM$"$

ETR$ 00$ 00$ ✖EFV00$SIM$"$

RPV$ 00$ 00$(TDF$!)$

00$



No'DDI'between'EFV'and'LDV/'SOF'

•  C24'geometric'mean'ra@o:'0.91'(90%'CI:'0.83M'0.91)'

•  no'effect'='1.0'•  RPV'less'effect'


DDI'between'PIr''and'HCV'Agents'ARV$ SOF$ LDS/$SOF$ SIM$

ATVr$or$ATV/$cobi$

00$ 00$(TDF$!)$

✖SIM$!$

DRVr$or$DRV/$cobi$

00$ 00$(TDF$!)$

✖SIM$!$

MM'='no'significant'effect'✖  ='do'not'use'“Monitor'for'TFVMassociated'adverse'events'in'EFV/FTC/TDF,'or'RTVMboosted'ATV'or'DRV+'TDF/FTC”'

AASLD/IDSA/IAS–USA.'hpp://www.hcvguidelines.org.'hpp://aidsinfo.nih.gov/contenqiles/lvguidelines/AdultandAdolescentGL.pdf;''German'et'al.'AASLD'2014'

DDI'between'INSTI'and'MVC'and'HCV'Agents'


DTG$ 00$ 00$ 00$

RAL$ 00$ 00$ 00$

EVG/cobi/TDF/FTC$

00$ ✖$ ✖$

MVC$ 00$ 00$ 00$



No'effect'of'RAL'on'LDV/'SOF'

•  C24'geometric'mean'ra@o:'0.89'(90%'CI:'0.81M'0.98)'

•  no'effect'='1.0'•  No'effect'SOF'on'RAL'


To$be$able$to$use$all$HCV$DAA,$what$ARV$regimen?$

1.  DRVr/RAL/'ABC/3TC'2.  RAL/'ETR/'TDF/FTC'3.  'DTG/ETR/TDF/FTC'4.  DTG/RPV/TDF/FTC'5.  Other'

Current:'DRVr'(BID)/'RAL/'TDF/'FTC;'Phenotype:''–  NRTI'–'Sensi@ve:'ABC,'TDF,'ZDV.'ResistantM'FTC,'3TC''–  NNRTI'Sensi@ve:'EFV,'NVP'–  PI'–'Sensi@ve:'SQV.'Reduced'suscep@bility'to'ATV,'FPV,'RTV'

ARV'Regimen'

•  Pa@ent'changed'to'DTG'(50'mg'BID)'+'RPV/TDF/FTC'(FDC)'9/2014'

What'would'you'do'with'the'ARV'regimen?'

1.  Follow'closely,'HIV'RNA's@ll'<200'2.  Add'DRVr'3.  Order'a'resistance'test'4.  pray'

Trofile'DNA'(11/7/14)'

GENOSURE'ARCHIVE'11/7/14'


ARV'Regimen'

•  Pa@ent'changed'to'DTG'(50'mg'BID)'+'RPV/TDF/FTC'(FDC)'9/2014'

•  11/21/2014'MVC'added'

Other'than'DDI,'does'HIV'coMinfec@on'change'HCV'DAA'selec@on/'outcome?'

1.  Yes'2.  No'

Osinusi A. AASLD 2014; 84

CharacterisKc$

No$ART$$N$=13$

ART$N$=$37$

1a$ 75%$ 81%$

HCV$RNA$ 6.1$ 6.0$

Fibrosis$stage$3$

38%$ 22%$

CD4$ 687$ 576$

Baseline'Characteris@cs'

•  Regimen:'EFV'(+/M'RAL)'16;'RPV'(+/M'RAL)'11;'RAL'10'

Results'•  SVR12'='98%'(49/50)'

– One'early'HCV'relapse'(wk'2'post'tx)'– One'late'relapse'HCV'at'week'36'post'tx'

•  HIV'safety'– No'change'HIV'RNA'in'offMART'group'– One'blip'in'ART'treated,'reMsupressed'–  CD4'stable'

•  Crea@nine'stable'to'week'12'post'treatment'– Mean'week'12:''crea@nine'change'+0.03;'CrCL'M3.8'– Mean'post'tx'week'12:'crea@nine'change'+0.04;'CrCL'+0.4'

Turquoise'1:'Abbvie'3'DAA'+'RBV'•  HIV/'HCV'

– GT'1,'naïve/'experienced,'cirrhosis'(CP'A)'– Stable'ART:'ATVr'or'RAL'

•  Paritaprevir/r'(PI)'+ombitasvir'+'dasabuvir'+'RBV'

Wyles D. AASLD 2014; 1939

CharacterisKc$ 12$week$N$=$31$

24$week$N$=$32$

HCV$genotype$1a$

97%$ 91%$

HCV$RNA$ 6.5$ 6.6$

Cirrhosis$ 19%$ 19%$

CD4$ 633$ 625$

ARV$=$ATVr$ 52%$ 38%$

Baseline'Characteris@cs'


CharacterisKc$ 12$week$N$=$31$

24$week$N$=$32$

Overall$SVR$12$ 94%$ 91%$

No$SVR$ 2$ 3$

Relapse$ 1$ 0$

Failure$during$tx$ 0$ 1$

Stopped$tx$ 1$ 0$

HCV$re0infecKon$ 0$ 2$

SVR12'


What'HCV'regimen'would'you'select?'

1.  SOF/'LDV'2.  SIM/'SOF'3.  SIM/'SOF'RBV'4.  IFN/'RBV/'SOF'5.  Other'6.  Need'more'informa@on'

Retreatment'of'SOF'failure'with'SOF/LDV'+'RBV:'GSMUSM342M1118'

Wk 0 Wk 12 Wk 36 Wk 24

LDV/SOF + RBV SVR12 SOF failures (n=51)

LDV/SOF SVR12 LDV/SOF failures

LDV/SOF + RBV SVR12 SOF failures (advanced liver disease)

Wyles D. AASLD 2014.

Baseline'Characteris@cs'LDV/SOF$+$RBV$12$weeks$

n=51$

Mean'age,'y'(range)' 54 (27‒68)

Men,'n'(%)' 31 (61)

Black/African'American,'n'(%)' 8 (16)

Hispanic/La@no,'n'(%)' 4 (8)

Mean'BMI,'kg/m2'(range)' 30.4 (21.1‒47.9)

IL28B'nonMCC,'n'(%)' 47 (92)

GT'1a,'n'(%)' 30 (59)

Mean'HCV'RNA,'log10'IU/mL'(range)' 6.2 (4.4‒7.3)

HCV'RNA'≥800,000'IU/mL,'n'(%)' 38 (75)

Prior'HCV'treatment,'n'(%)'

SOF'+'PEG/RBV' 25 (49)

SOF'±'RBV*$ 21 (41)

SOF'placebo†' 5 (10)

Cirrhosis,'n'(%)' 15 (29) Wyles D. AASLD 2014.

24

98 100 100 98 98 98

0

20

40

60

80

100

Wk 1 Wk 4 Wk 8 EOT SVR4 SVR12 SVR24

HC

V R

NA

<LLO

Q, %

Error'bars'represent'95%'CIs.'EOT,'end'of'treatment.'

51/51 12/51$ 51/51$

HC

V R

NA

<LLO

Q, %

50/51$50/51$ 50/51$50/51$

OnMTreatment'Viral'Kine@cs'and'SVR'Rates'

Wyles D. AASLD 2014.

14/14'SOF/RBV'failures'achieved'SVR12'with'SOF/LDV'for'12'weeks.'Osinusi&A.&EASL&2014.&

But'our'pt'failed'SOF'plus'an'NS5A'(DCV)…'

•  What'is'his'resistance'profile'post'failure'likely'to'look'like?'– SOF'resistance?'– DCV'resistance?'

•  What'is'the'impact'of'NS5A'resistance'on'treatment'outcomes?'

•  Is'there'any'data'on'reMtreatment'of'these'pa@ents?'

'

SOF'Resistance'

•  AASLD'2013:'No'S282T'in'4'phase'3'studies'–  Studies'across'GTs'1M4'(NEUTRINO,'FISSION,'FUSION,'POSITRON)'–  226'nonMSVRs:'221'UDS'(1%'detec@on'level)'

•  No'S282T'iden@fied'–  1/294'nonMSVRs'with'S282T'(Svarovskaia&E.&CID&2014)&

•  AASLD'2014:'No'S282T'in'phase'3'SOF/LDV'–  L159F'+/M'V321A'seen'as'TEVs'–  15%'L159F'with'SOF;'1%'with'SOF/LDV'–  impact'on'response?'

•  1.6%'at'baseline'w/'L159F:'100%'SVR'in'SOF/LDV'(23/23)'

Svarovskaia$E.$AASLD$2013.$Gane$E.$#43$AASLD$2014.$

Evolution of sofosbuvir resistance in the subject with S282T.

Svarovskaia E S et al. Clin Infect Dis. 2014;59:1666-1674

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: [email protected].

NS5A'Inhibitor'Resistance'

•  Similar'resistance'papern'for'1st'gen'NS5A'with'respect'to'GT'1a'and'1b'

Kitrinos'KM.'#1949'AASLD'2014.'Wang'C.'AAC'2013'

Long'term'DCV'followMup'from'AASLD'

Reddy'KR.'AASLD'2014.'

Long'term'DCV'followMup'from'AASLD'

•  Median'followMup'ranged'from'41M123'weeks'– Longer'in'pts'treated'with'DCV/P/R'

•  Predominant'NS5A'RAVs'– 1a:'Q30E/K/R,'L31M/V,'Y93H/C'''1b:'L31M/V'+'Y93H'

•  Persistence'of'NS5A'RAVs'– 86%'(63/73'1a)'and'95%'(56/59'1b)'by'popula@on'at'last'followMup'

– Contrast'to'41%'(1a)'and'29%'(1b)'at'last'followMup'for'NS3'RAVs'

Reddy'KR.'#1965'AASLD'2014.'Wang'C.'AAC'2013.'

Impact'of'NS5A'baseline'resistance'is'contextual'

•  IFN'vs'IFNMfree'•  Strength'of'surrounding'DAAs'

Kitrinos'KM.'#1949'AASLD'2014.'Manns'M.'EASL'2014'

38%'SVR12'in'ASV/DCV'with'baseline'NS5A'RAVs'(compared'to'85%'overall)'

Baseline'NS5A'resistance'and'SOF/LDV'

•  Deep'sequencing'analysis'of'baseline'samples'(n=1904)'in'phase'2/3'SOF/LDV'studies'– ELECTRON,'LONESTAR'and'ION'studies'

Sarrazin'C.'#1926'AASLD'2014.'

97%'

93%'

GT$1$(n=2137)$

98%'95%'

GT$1b$(n=529)$

96%'92%'

GT$1a$(n=1602)$

NS5A'RAVs'No'NS5A'RAVs'

SVR12'(%)'

Baseline'NS5A'resistance'and'SOF/LDV'

Sarrazin'C.'#1926'AASLD'2014.'

<100X'

>100X'

No'RAVs'

Impact'of'baseline'NS5A'RAVs'on'outcomes'in'retreatment'

•  No'pa@ents'had'SOFMassociated'variant,'S282T,'detected'at'baseline''–  2'pa@ents'had'NS5B'treatmentMemergent'variant'L159F'at'baseline'and'

achieved'SVR'

'

Wyles'D.'AASLD'2014'*1'pa@ent’s'baseline'results'were'not'available.'

n=6/6$

100%$SVR$98%$SVR$

n=43/44$

12%$NS5A$RAVs$

n=6/50'

88%$No$NS5A$RAVs$at$baseline$

n=44/50*'

And'of'course'this'is'the'single'LONESTAR'pa@ent…'

Lawitz'E.'#215'AASLD'2013.'

So'we'might'be'able'to'get'away'with'24wks'of'SOF/LDV,'but…'

Why'not'just'avoid'the'NS5A'class?'

•  This'makes'the'most'sense'intui@vely'•  What'is'the'data'with'SOF'+'SIM'+/M'RBV'

– This'is'an'FDA'approved'regimen'• What'does'the'label'say?'•  Do'the'Guidelines'help…not'really.'

– RealMworld'data'with'this'regimen?'•  Very'liple'in'HIV+'

•  Special'considera@ons'in'a'treatment'experienced'cirrho@c?'

COSMOS:'Data'in'F3/F4'93' 97'

89'

0'

10'

20'

30'

40'

50'

60'

70'

80'

90'

100'

F3/F4' F3' F4'

Lawitz'E.'Lancet'2014.'

18'23'41'

89' 89'

Naïve' Null'

12'weeks'

24'weeks'

9' 9'

F4'only'

No'conclusion'can'be'drawn'on'the'u@lity'of'RBV.'

FDA'label'indica@ons'for'SOF/SIM'

Tes@ng'for'Q80K'“is'not'strongly'recommended'but'may'be'considered.”'No'guidance'on'RBV'is'offered.'

Olysio'package'insert'(11/2014).'

Real'world'data:'HCV'Target'

SOF/SIM'groups:'60%'experienced'(27%'PI'failure),'57%'cirrhosis'(47%'decompensa@on).'' ' ' ' ' ' '3%'HIV'CoMinfected'

Jensen'D.'#45'AASLD'2014.'

Real'world'data:'HCV'Target'

Jensen'D.'#45'AASLD'2014.'

81'85'

79'

0'

89' 92'87'

75'

0'10'20'30'40'50'60'70'80'90'100'

All' NC' Cirr' DC'

PI'failure' No'PI'

No'data'on'Q80K;'vast'majority'did'not'have'it'tested.'97%'concordance'between'SVR4'and'SVR12.'

SVR4'

TRIO'network'realMworld'experience'

65%'of'GT1'received'SOF/SIM'+/M'RBV;'~50%'treatment'experienced.'

Flamm'S.'#983'AASLD'2014.'

TRIO'network'realMworld'experience'

No'data'on'Q80K'presented.'

Flamm'S.'#983''AASLD'2014.'

SIRIUS'Study'•  DoubleMblind'study'•  Treatment'experienced'cirrho@c'pa@ents'

– All'failed'both'Peg/RBV'then'P/R/PI'

– Groups'were'well'matched'•  Plt'<100k:'18%'vs'17%'•  ALB'<3.5:'8%'vs.'17%'

Bourliere'M.'#LBM6'AASLD'2014.'

SIRIUS'Study'

Bourliere'M.'#LBM6'AASLD'2014.'Bourliere'M.'#82'AASLD'2014'

HCV'regimen'

•  SIM/'SOF/'RBV'10/10/14'– Week'2'10/24'– Week'4'11/07'

HCV'RNA'

BACKUP'

•  Phenotype 2004: – NRTI - Sensitive to ABC, ddI, d4T, TDF, ZDV.

Reduced susceptibility to FTC, 3TC – NNRTI - Sensitive to EFV, NVP, DLV – PI - Sensitive to SQV. Reduced susceptibility

to ATV, FPV, IDV, LPV, NFV, RTV

HIV'RNA'

HCV'RNA'


Date post:	15-Jul-2015
Category:	Health & Medicine
Upload:	uc-san-diego-antiviral-research-center
View:	99 times
Download:	2 times

Update from the American Association for the Study of Liver Diseases Meeting

Health & Medicine